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Summary 
Interleukin 2 (I1:2) receptors expressed on the surface of activated T cells and natural killer (NK) 
cells exhibit a variety of affinity  states depending on their subunit composition. Low-affnity 
binding is associated with a 55-kD c~ chain, intermediate-affnity binding with a 70-75-kD 
chain, and high-affnity binding with a bimolecular complex of the c~ and fl subunits. In a previous 
study of the 1I:2 receptors expressed on NK cells obtained from cancer patients after in vivo 
I1.2 therapy, we documented  a discrepancy between the level of fl chain and the level of intermediate- 
affinity I1.-2 binding sites expressed on the cell surface. Based on this result, we postulated that 
formation of intermediate-affnity receptor sites required a component in addition to the ~ chain, 
and that this component was present at limiting levels in the patient NK cells. In the present 
study we have examined the structure of the intermediatc*affnity receptor complex using monoclonal 
antibodies that recognize the fl chain, but that do not interfere with its ability to bind I1-2. 
Evidence is presented establishing the physical association of a novel protein of 64 kD with the 
chain in  intermediate-affnity I1-2  binding sites. This  molecule,  termed I1.2R  3'  chain, 
coprecipitated with B chains prepared from cells that had been incubated with I1.2, but was 
undetectable in immunoprecipitates prepared in the absence of I1-2. Examination of 3' chain 
expression in post-I1-2 therapy NK cells, where only low levels ofintermediate-affnity I1-2 binding 
were detectable,  revealed that the 3~ chain was associated with, on average, only 10-12% of the 
3  chains expressed on such cells. This contrasted with approximately equal levels of ~  and 3' 
chain expression on YT cells, a cell line that has both high levels of cell surface/~ chain expression 
and high levels of I1-2 binding. Thus, the ratio of 7  chain to ~ chain present in the immuno- 
precipitates  roughly correlated with the proportion of/3 chain involved in intermediate-affnity 
receptor sites. This result suggests that the 64-kD 3~ chain is the component responsible for 
regulating the affinity of I1-2 association with the/~ subunit. By further defining the structural 
components necessary for I1-2 receptor formation, these studies provide additional insight into 
mechanisms whereby lymphocytes might regulate their responsiveness  to IL-2. 
I 
1.2 is a 15-kD glycoprotein produced by activated helper 
T lymphocytes that is responsible for activating and main- 
taining proliferative and cytolytic responses mediated by both 
T  and NK cells (1-3).  These cells are activated  by soluble 
I1.-2 after its interaction with specific cell surface receptors. 
The I1.2R is made up of at least two subunits, o~ (p55, Tac) 
and ~ (p70-75),  that noncovalently associate on the cell sur- 
face to produce a high-affnity receptor complex capable of 
binding II.-2 with an equilibrium Ka of ~5-20 pM (4-9). 
Each of the chains present in the I1.2R complex can bind 
I1.2 independently of the other, with either low (o~, Kd  = 
5-20 nM) or intermediate (fl, Ka  =  0.5-2.0 nM) affinity 
(2, 7-11). Low-affnity receptors bind I1.-2 with both rapid 
association and dissociation rates, while intermediate-affnity 
receptors, in contrast, have slow association and dissociation 
rates (2, 10, 11). The interaction of the oe and fl chains allows 
the formation of a high-affnity receptor with kinetic and 
equilibrium binding properties that are a cooperative com- 
posite of its constituent chains,  such that the high-affnity 
receptor combines the rapid rate of I1.2 association  charac- 
teristic of low-affnity receptors with the slow rate of dis- 
sociation characteristic of intermediate~affnity receptors. This 
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with an equilibrium  affinity one to three orders of magni- 
tude  higher  than  either  the  low-  or  intermediate  affinity 
receptor. When expressed on lymphoid cells, both the inter- 
mediate and the high-affinity receptor can internalize IL-2 and 
mediate biological effects (12,  13). 
In a previous study examining the I1.-2 binding properties 
of the IL-2R expressed on human NK cells activated in vivo 
by systemic infusions of IL-2, we documented high levels of 
IL-2R/3 chain  expression on NK cells  obtained  after II.-2 
therapy,  a  finding  inconsistent  with  the  low  levels  of 
intermediate-affinity IL-2 binding detected on these cells (14). 
No high-affinity IL-2R were detectable, and upon in vitro 
culture  in  IL-2,  these cells responded  exclusively through 
intermediate-affinity receptors. It was concluded from these 
studies that the regulation of functional IL-2R formation could 
not be determined solely by the level of/3 chain expression 
at the cell surface,  and that some other IL-2R subunit may 
be needed to allow the formation of a functional intermediate- 
affinity II~2R (14). This conclusion was in agreement with 
other studies that had demonstrated a requirement for some 
other molecule(s) in addition to the p55 oL and p70/3 chains 
for the formation of functional IL-2R (15-19).  Based on quan- 
titative kinetic studies, Ringheim et al. (19) proposed a role 
for a putative II~2R 3" chain that influenced the equilibrium 
binding affinity of the receptor complex by controlling the 
rate of dissociation of bound II.-2. According to this hypoth- 
esis, cells (such as the leukemic cell line YT,  or lymphoid 
cells transfected with the/3 chain cDNA) that bind Ib2 with 
intermediate affinity express/33' complexes. In contrast, iso- 
lated/3 chains (18) or/3 chains expressed on nonlymphoid 
cells  (19) bind II.-2 with 50-100-fold lower affinity (Ka  = 
70 vs.  0.5-2.0  nM for intermediate-affinity  binding). 
In attempts to identify additional components of the human 
IL-2R,  a variety of receptor-associated  proteins  have been 
reported by a number of investigators (20-23), although none 
have  received  universal  recognition  as  an  IL-2R 3'  chain. 
Takeshita et al. (24) have observed a 64-kD molecule in high- 
affinity IL-2R complexes that was only detectable in the pres- 
ence of II.~2, and have proposed that this molecule be termed 
IL-2R 3' chain. The present study was undertaken to deter- 
mine whether the presence of this additional receptor subunit 
could be linked to the formation of a functional intermediate- 
affinity IL-2R. In vivo activated NK cells provide a unique 
model system with which  to pursue these studies,  in that 
only a small fraction of the/3 chains expressed on these cells 
are involved in intermediate-affinity II.-2 binding, while the 
majority of the/3 chains present do not bind IL-2 with an 
appreciable affinity.  Using two newly developed anti-Ilc2R 
/3 chain mAbs, the same 64-kD protein observed by Takeshita 
et al.  (24) in high-affinity  receptors was detected in inter- 
mediate-affinity II~2R. In accordance with the proposal of 
Takeshita et al. (24), we have also termed this molecule IL-2R 
3" chain.  The p64 3' chain physically associated with the 3 
chain in the presence of IL-2, while in the absence of IL-2 
no association of 3' chain with/3 chain was detected, con- 
firming the absolute requirement for IL-2 bound in the receptor 
complex for the detection of 3' chain associated with/3 chain. 
Furthermore, the low level of IL-2R 3' chain that was associated 
with the 3 chain in immunoprecipitates prepared from post- 
therapy NK cells corresponded to the low level of intermediate- 
affinity IIr  binding detected on these cells. No IIr  3' was 
detected associated with the 3 chain in fibroblasts transfected 
with the 3 chain cDNA. These results suggest that the IL-2R 
3' chain may play a crucial role in lymphoid cells, regulating 
IL-2R formation by modulating the ligand binding proper- 
ties of the 3  chain. 
Materials  and Methods 
Patients.  All patients from whom samples were obtained were 
enrolled in phase I clinical trials of IL-2 currently underway at the 
University of Wisconsin Comprehensive Cancer Center, and had 
progressive metastatic renal cell carcinoma or malignant melanoma 
that was incurable by surgery. Patients received IL-2 at 1-3  x  106 
U/m2/d as a 96-h continuous  infusion for a consecutive 2-4 wk, 
as described previously (25-27). All patients signed consent forms 
for in vivo and in vitro studies approved by the University of Wis- 
consin Committee for the Protection of Human Subjects. Patient 
PBMC  (PBL) were  obtained  by Ficoll-Hypaque  separation  of 
heparinized blood specimens drawn 24 h after each 4-d cycle of 
ID2, and were either used directly or cryopreserved by controlled 
rate freezing in 10% DMSO, followed by storage at  -135~  until 
later use. For purification of NK cells from fresh peripheral blood, 
PBL were depleted of T cells by staining with biotinylated anti- 
CD5 and avidin-FITC, followed by sorting on a MACS magnetic 
cell separator (Miltenyl Biotec, Sunnyvale, CA) (28). Purification 
typically  yielded  NK  cell  populations  that  were  94-99% 
CD56+CD3 -.  For  some patient  specimens, the percentage  of 
CD56+CD3 -  NK cells in the peripheral blood obtained after in 
vivo IL-2 therapy exceeded 92%, and no further cell separation was 
performed. 
I1_,2.  rIL-2 was generously provided by Hoffmann-La Roche 
(HLR),  Inc. (Nutley,  NJ)  via  the  National  Cancer  Institute- 
Biological Response Modifiers Program (NCI-BRMP; Frederick, 
MD) for clinical treatment  and in vitro studies. All IL-2 units are 
based on the NCI-BRMP standard for unit determination.  The 
specific activity of HLR II_-2 is 1.5  x  107 U/mg protein. 
CellLines.  The YT cell line (29) expresses a low level of Ib2R 
c~ chain and a relatively high number (~o12,000-20,000/ce11) of 
intermediate-affinity II~2 binding sites (7, 8, and unpublished ob- 
servations). Chinese hamster ovary (CHO) fibroblast cells trans- 
fected with either the cDNA for the IL-2R 3 chain (CHO 3) or 
both the IL-2R oe and 3 chain cDNAs (CHO eft3) have been de- 
scribed previously (19). 
Production of mAb to the IL2R ~  Chain.  BALB/c mice were 
immunized (three times at 2-3-wk intervals) with a clone of CHO 
cells stably expressing 1-3  x  106 copies per cell of a truncated ver- 
sion (3~1; see reference 19) of human rIL-2R 3 chain. The cyto- 
plasmic-deletion mutant of the 3 chain was chosen over full-length 
3 because of its much higher (10-100x) expression on the surface 
of CHO cells (19), Splenocytes were harvested and fused with the 
nonproducing  hybridoma line P3X63.653, followed by hybrid se- 
lection in HAT medium. Culture supernatants were tested for the 
presence of anti-3 antibodies by indirect fluorescence using CHO 
3261 and wild-type CHO cells as targets and PE-conjugated goat 
anti-mouse IgG as a secondary reagent. Two hybrids (designated 
341 [IgGl] and 561 [IgG2a]) were selected from the initial screen 
and subcloned by limiting dilution.  Purified antibody was isolated 
from culture supematants of the clones by affinity chromatography 
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Antibodies.  MikB1 and Mik/33 (30) were kindly provided by 
M. Tsudo (Unitika  Central  Hospital,  Kyoto, Japan).  TU27 (31) 
was the generous gift of K. Sugamura (Tohoku University, Sendai, 
Japan). Control IgG1 (MOPC21) and IgG2a (UPC10) were pur- 
chased from Sigma Chemical Co.  (St. Louis, MO). 
12sI-IL2 Binding Assays.  Binding assays with 1~I-Ib2 were per- 
formed as described previously (14, 19). 
FACS  |  Analyses.  FACS  |  staining (Becton Dickinson & Co., 
Mountain View, CA) was performed as described previously (14). 
For staining with mAbs 341 and 561, cells were incubated with 
purified mAb at 20 #g/m1, followed  by staining with PE-conjugated, 
isotype-specific (i.e., GAM IgG1 for staining with 341 and GAM 
IgG2a for staining with 561) goat anti-mouse reagents (Southern 
Biotechnology  Associates, Birmingham,  AL). 
Iodination and Immunoprecipitation.  These were performed es- 
sentially as described previously (14), except that calls were ra- 
dioiodinated with Iodogen (Pierce Chemical Co., Rockford,  IL). 
Typically, 5  x  107 cells were resuspended at 2  x  107 cells/ml in 
HBSS. 5 mCi Na12SI (Amersham Corp.,  Arlington  Heights,  IL) 
were added to cells without carrier NaI. 500-/~1 aliquots of cells 
+ nsI were added to glass tubes  coated with  150/~g Iodogen. 
After  30 min  at room temperature,  cells were washed  and re- 
suspended in binding buffer (RPMI 1640 with 25 mM Hepes, pH 
7.4, and 2 mg/ml BSA). For experiments in which cells were in- 
cubated in Ib2, Ib2 was added to a final concentration  of 50-80 
nM,  to insure  complete  saturation  of intermediate-a~nity  Ib2 
binding  sites. After incubation  for 60-90 rain on ice, cells were 
pelleted, washed in ice cold HBSS, and lysed in NP-40 lysis buffer 
(0.5% NP-40,  140 mM NaC1, 5 mM EDTA, 100/~g/ml PMSF, 
and 10 #g/ml each leupeptin,  aprotinin,  and antipain).  After 30 
rain on ice, lysates were cleared by centrifugation  for 20 min at 
14,000  rpm  in  a  microfuge.  Lysates were  preincubated  with 
nonspecific mouse IgG agarose (Sigma Chemical Co.), followed 
by incubation for 3-6 h with specific  antibody coupled to Sepharose 
beads (Aminolink Sepharose; Pierce Chemical Co.) or with Gam- 
maBind Plus Protein G beads (Pharmacia LKB Biotechnology) that 
had been precoated with 25/~g of antibody. Immunoprecipitates 
were washed extensively, followed by addition of 7.5/~1 of boiling 
buffer (20 mM Tris, pH 7.5, 5% ~ mercaptoethanol,  0.3% SDS) 
and heating  at 95~  for 2-3 min.  Precipitates were duted from 
beads into 120 #11EF sample buffer (9.5 M urea, 2% [wt/vol] NP- 
40,  1.6% pH 5-7 ampholines [Pharmacia LKB Biotechnology], 
0.6% pH 3.5-10 ampholines, 5% ~-mercaptoethanol) and analyzed 
by two-dimensional (2-D) IEF/SDS-PAGE. 5/~g of bovine muscle 
actin (Sigma Chemical Co.) was added to each sample as an in- 
ternal  IEF standard  (pI =  5.4-5.5,  molecular mass  =  45 kD). 
Similar results were obtained when 10 mM dithiothreitol  was used 
as the reducing  agent. 
2-D IEF/SDS-PAGE.  This  was performed  according to the 
method of O'FarreU (32), with modifications by  Jones (33). Samples 
were loaded on 15-cm IEF tube gels (9.2 M urea, 4% acrylamide, 
2% [wt/vol] NP-40, 1.6% pH 5-7 ampholines, and 0.6% pH 3.5-10 
ampholines) that had been prefocused at constant 2 mA until 800 
V was reached. IEF was for 12,000-14,000 V-h at 800 V, followed 
by 2,000 V-h at 1,000 V. Tubes were extruded  into SDS sample 
buffer (62.5 mM Tris, pH 6.8, 10% [wt/vol] glycerol, 2.3% SDS, 
0.002%  bromophenol  blue) and stored at  -20~  until second 
dimension gels were run. For second dimension, tubes were thawed 
quickly at 37~  layered onto 10% polyacrylamide gels containing 
a 5-cm stacking gel, and subjected to electrophoresis at 30-40 mA 
constant  current  per gal. After electrophoresis, gels were stained 
with coomassie blue, fixed, dried, and exposed to phosphor  im- 
aging plates (see below). 
Autoradiographic Detection by Storage Phosphor  (Phosphorimager)  De- 
tection (34).  After staining, fixing, and drying, gds were exposed 
to photostimulable storage phosphor imaging phtes (Molecuhr Dy- 
namics, Sunnyvale, CA) for 3-5 d, followed by development and 
quantitation  on a Phosphorimager  (400A; Molecular Dynamics) 
using  Image Quant software. Similar images to those presented 
were obtained  on samples visualized by conventional autoradio- 
graphic exposure to x-ray film. However, the use of the phos- 
phorimager provided ,,~ 100 times greater sensitivity in our hands 
than  standard x-ray film. In addition,  a linear dynamic range of 
magnitude and sensitivity for the storage phosphor imaging plates 
aUowed  accurate comparisons to be made between signals that varied 
significantly in intensity.  Digitalized  images were analyzed and 
printed on a LaserJet II printer (Hewlett-Packard  Co., Palo Alto, CA). 
Results 
Isolation and Characterization of Anti-IL.2R ~  Chain  mAbs 
341 and 561.  mAbs recognizing the human Ib2R/3 chain 
were developed by immunizing  BALB/c  mice with  CHO 
cells expressing recombinant human/3 chain (for details,  see 
Materials  and  Methods).  This  procedure  resulted  in  the 
identification  of two  unique  mAbs,  341  (IgG1)  and  561 
(IgG2a). FACS  |  analysis of YT cells, which express the IL 2R 
/3 chain as predominantly intermediate-affinity IL-2 binding 
sites  (7,  8,  14),  and CHO cells transfected with either the 
full-length/3 chain cDNA or both the ot and/3 chain cDNAs 
(19), confirmed that these mAbs recognize the/3 chain (Fig. 
1). When these mAbs were characterized with respect to their 
effect on Ib2 binding, neither was found to inhibit IL,2 binding 
to high- or intermediate-affinity IL2R. As shown in Fig. 2, 
mAb 341 had no effect on II.,2 binding to the high-affinity 
IL-2R expressed on HUT 102 cells (Fig.  2 A) or to the cff/3 
complex expressed on CHO cells  transfected with both ot 
and/3 chain cDNAs (19) (Fig. 2 B). Similarly, mAb 341 had 
no inhibitory effect on IL-2 binding to the intermediate-affinity 
Ib2R expressed on YT cells (Fig.  2 C).  Results similar to 
those shown for mAb 341 in Fig. 2 were obtained with mAb 
561 (data not shown).  In contrast,  mAb TU27,  known to 
inhibit the binding of II~2 to the 13 chain (14,  31), blocked 
the binding of 12sI-IL-2 to the intermediate-affinity sites ex- 
pressed on YT cells (Fig.  2 C). TU27 similarly eliminated 
12sI-IL-2 binding to the high-affinity sites on HUT 102 cells 
(Fig.  2 A) and to the or~~3 complexes on transfected CHO 
cells (Fig.  2 B), reducing the II-2 binding to these cells to 
an affinity characteristic  of the low-affinity c~ chain.  One- 
dimensional SDS-PAGE analysis of immunoprecipitates pre- 
pared from surface-iodinated YT cells confirmed that mAbs 
341  and 561  recognized the same 70-kD protein  that  was 
precipitated by a panel of anti-/3  chain mAbs including the 
Endogen anti-/3 chain mAb, MikB1 (30), Mikfl3 (30), and 
TU27 (31) (data not shown). Thus, mAbs 341 and 561 are 
functionally comparable to Mik/33 (30) and TUll (35): these 
antibodies all bind to the IL-2R/3 chain,  but do not com- 
petitively inhibit  IL.2 binding  to the/3  chain. 
Competitive binding assays (Table  1) showed that  mAbs 
341, 561, and Mik/33 inhibited up to 100% of one another's 
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Figure 1.  Flow cytometric analysis ofmAbs 341 and 561 staining on cells expressing the Ib2K fl chain. CHO cells either untransfected (CHO/Wild), 
transfected  with the fullqength Ib2K B chain cDNA (CHO B), or transfected with both full-length ot and/3 chain cDNAs (CLIO ot~), as well as 
YT cells, were incubated with 20 #g/ml of control IgG1, control IgG2a, mAb 341, or mAh 561. After 30-60 min on ice, cells were washed twice 
and stained with the appropriate isotype-spectfic goat anti-mouse IgG-PE for 30 min. Positive staining is indicated by the solid histograms, while 
control staining is presented as an open histogram. As expected,  CHO cells that had not been transfected with the B chain cDNA (CliO~Wild) had 
levels of staining with mAbs 341 and 561 that were indistinguishable from control staining,  such that the overlaying of histograms as shown resulted 
in masking of the control histogram. 
binding, while TU27 and MikB1 modulated the affinity of 
binding of mAbs 341 and 561 such that at the highest con- 
centrations of TU27 or Mik/$1, the affinities of 341 and 561 
were reduced approximately threefold. Similarly, in a reciprocal 
experiment, mAbs 341 and 561 reduced the affinity of TU27 
binding approximately twofold. Competitive  binding results 
with these same antibodies were confirmed by two-color 
FACS  ~ analyses using isotype-specific secondary reagents (data 
not shown). In these experiments, YT cells could be double 
stained  with  combinations  of  mAbs  341  and  Mike1 
(341/MikB1), or with 561/TU27, but not with 341/561. 
Furthermore, mAbs 341, 561, and Mik/33,  but not TU27 
or Mik/31, recognized a human/mouse chimeric ~ chain in 
which the NH2-terminal 75 amino acids were routine and 
the remainder human (R. Kobb, unpublished observations). 
These findings indicate that the epitopes on the human IL-2R 
Table  1.  Summary  of Results of Competitive Binding Assays with Anti-IL-2R /3 Chain mAb 
Effect on 
mAb  Kd*  IL-2 binding  Competitive inhibition 
nM 
341  10.5  Noninhibitory 
561  6.7  Noninhibitory 
TU27  4.9  Inhibitory 
Mik/~l  13.0  Inhibitory 
MikB3  1.1  Noninhibitory 
Reciprocally inhibit the binding of one  another  to  the ~  chain;  reduce the affinity of binding 
of TU27  approximately twofold. 
Reduce  the  affinity of 341  and  561  binding by approximately threefold. 
Inhibits  100%  of binding of 341  and  561. 
* The Kas of binding to CHO B261 cells (19) for mAbs 341,  561,  and TU27 were determined by competitive binding assays employing the cor- 
responding Bolton Hunter reagent-radioiodinated mAb probes. The Kd (K~) of Mike1 binding was inferred from competition curves using t2Sl- 
TU27, titering MikB1  against a constant amount of lzSI-TU27. Similarly, the Ka (Ki) of binding for Mike3 was derived from competition curves, 
titering Mike3 against a constant amount of either 12si-341 or 12si-561. 
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Figure 2.  Scatchard  analysis of the influence of mAbs 341 on 12sI-IL-2 
binding: 341 does not inhibit II~2 binding. HUT 102 cells expressing both 
high-affinity and low-affinity IL-2K (A), CHO transfected with cDNAs, 
encoding the c~ and B chains (/3), and YT cells, which express predomi- 
nantly intermediate affinity II.-2R (C), were incubated for 20-30 rain on 
ice with 50 #g/ml of either  control mAb (O-O), mAb 341 (O-O), 
or TU27 ( O"" O). Cells were then incubated with increasing concentra- 
tions of 12Sl-IL2. Bound and flee ligand were separated by centrifugation 
through silicone/paraffin oil. Results are presented as Scatchard plots of 
the binding data.  Under the conditions used in the experiment  shown 
in B, essentially all of the II.-2 binding to CHO c~//~ cells was to the c~/B 
complex and was of a relatively high affinity (Ka  =  44 pM),  allowing 
evaluation of the influence of the antibodies on IL-2 binding to the c~/~ 
complex. In the experiment shown in A, the Ka of high-affinity binding 
to HUT 102 cells was estimated at 5 pM, while the Kd of intermediate- 
affinity binding to YT cells (C) was estimated  at 1.3 nM. 
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3 chain recognized by mAbs 341 and 561 are similar and may 
lie within the COOH-terminal segment of the extracellular 
portion of the fl chain. They are distinct, however, from those 
recognized by anti-3 chain mAb that (unlike mAbs 341 and 
561) interfere with IL-2 binding. 
Detection of  p64JL  2R T Chain in Intermediate-Affinity IL  2R. 
Takeshita et al. (24) have reported that a 64-kD molecule is 
physically associated with the c~ and ~/subunits in the high- 
affinity IL-2R complex. The presence of II~2 bound to the 
high-affinity IL-2R complex was required for the detection 
of p64. Based on these observations,  it was important to de- 
termine whether p64 was also present in the intermediate- 
affinity IL-2R complex found on the surface of YT cells (which 
expressed no detectable ot chain), thus proving the associa- 
tion of this molecule with the ~ chain. It was therefore es- 
sential to first establish whether mAbs 341 and 561, like TU11 
(24, 35), were capable of recognizing and immunoprecipitating 
the putative IL-2R 3` chain physically  complexed to the j8 chain. 
YT cells were radioiodinated and then detergent solubi- 
lized.  Immunoprecipitates prepared with anti-~ mAb were 
analyzed by 2-D IEF/SDS-PAGE  for the presence of the ~/ 
chain. As shown in Fig.  3 A, in the absence of IL-2 only 
a single specific spot was observed on the 2-D gel. A similar 
spot was observed with Mikt81 and TU27 (data not shown), 
consistent with its identification as the IL-2R B chain. When 
iodinated YT cells were allowed to equilibrate with I1~2 be- 
fore detergent solubilization, a protein of ~64 kD formed 
a stable complex with the ~  chain (Fig. 3 B). Both mAbs 
341 and 561 were able to recognize this complex (Fig. 3 B), 
as was Mike3 (data  not shown). Under the reducing and 
denaturing conditions employed in the 2-D IEF/SDS-'PAGE 
system, this 64-kD protein had a slightly more acidic pI than 
the larger ~/chain, consistent with earlier work (24). Based 
on this finding we have termed the p64 molecule Ib2R 3' 
chain, as proposed by Takeshita et al. (24). The broad migra- 
tion of the ~  and 3` chains in both the IEF and molecular 
mass separations is likely due to variability in the degree of 
iodination on tyrosine (36). It is unlikely that these two spe- 
cies represent differentially  glycosylated forms of the same 
protein (i.e., the ~ chain) since increases in glycosylation would 
tend to make the larger protein more acidic, a result that has 
been directly demonstrated for the IL2R B chain (37). Pep- 
tide mapping experiments revealed that the/3 and 3` chains 
had dramatically different sensitivities to V8 protease diges- 
tion (24 and our unpublished observations), and confirmed 
that the 3` chain is a unique chain and not simply a processed 
form of the B chain. 
The additional spot seen in Fig. 3 B in the 50-56-kD range 
has not been reproducibly observed, although it is noteworthy 
that others have described II.-2R-associated molecules in this 
size range (p56 [22] and p561ok [38]). This species is not the 
IL-2R c~ chain, since c~ chains migrate to a position even more 
acidic than the 3' chain (our unpublished observations). 
The experiments shown in Fig. 3 were all performed in 
the absence of chemical crosslinkers, providing evidence for 
the stability of the 83' complex when Ib2 is present. When 
crosslinking with the thiol-deavable crosslinker,  DSP, was 
performed on YT cells, association of the 3` chain with the Figure 3.  2-D IEF-SDS PAGE analysis of IL-2R/~ and IL-2R/33, com- 
plexes isolated from intermediate-affinity receptor-bearing YT cells. (.4) 
Cell surface iodinated YT cells were detergent solubilized and immuno- 
predpitated with either control IgG agarose beads or mAb 341-coupled 
Sepharose beads. First-dimension IEF gels are oriented acidic (H +) to basic 
(- OH) (left to right). Standard molecular masses are indicated at the left. 
(B) YT cells were iodinated and incubated with 80 nM I1.,2 for 120 rain 
on ice, followed by detergent solubilization  and immunoprecipitation with 
either control IgG agarose, 341-coupled Sepharose beads, or 561-coupled 
sepharose beads.  Immunoprecipitates were analyzed as in A. The small 
arrow at the top indicates the position of  bovine muscle actin (pI =  5.4-5.5). 
Stained,  fixed, and dried gels were exposed to phophorimaging screens 
for 4-5 d. 
/3 chain was again observed only when IL2 was present (Table 
2, Exp. 5). This result indicates that 11,2 is required for the 
isolation of/33' complexes and suggests that stable/33' com- 
plexes are not preformed on the cell surface. We can not rule 
out the possibility,  however, that in the absence of I1,2, the 
/3 and 3' chains are positioned in a way that prevents them 
from being physically crosslinked.  When 1% digitonin was 
used as the solubilizing detergent rather than 0.5% NP-40, 
no difference was seen in the relative  abundances of/3 and 
3' on I1,2-treated YT cells (our unpublished observations). 
This finding supports the view that the I1,2-/3/3'  complex 
is stable  under mild nonionic lysis conditions and that its 
preservation is not improved by the use of the milder lysis 
conditions (i.e., 1% digitonin) that have been shown to re- 
sult in improved stability of labile membrane complexes in 
other systems  (39,  40). 
Association of  lL2R 7  Chain with Functional  IL2R Expres- 
sion.  Our previous study characterizing the I1,2R expressed 
on NK cells that had been activated  in vivo by continuous 
infusion I1,2 demonstrated that the majority of the/3 chains 
expressed on those cells did not bind I1,2 with appreciable 
affinity (14). This suggested that some critical receptor com- 
ponent (such as the 3' chain described above) might be present 
in limiting amounts on the surface of these cells. Based on 
the results shown in Fig. 3, it was of interest to determine 
whether the 64-kD 3' chain was a component of the I1,2R 
complexes isolated  from post-I1,2  therapy  NK  cells  and 
whether its abundance relative  to that of the/3 chain was 
consistent with a hypothetical role as a modulator of the ability 
of the/3 chain to bind I1,2. NK cells obtained from patients 
after II.-2 therapy were examined for the expression of both 
/3 and 3' chains.  As shown in Fig. 4 only a small fraction 
of the/3 chains immunoprecipitated from lysates prepared 
from surface-iodinated patient NK cells were complexed with 
the 7 chain. Consistent with our findings with YT cells (Fig. 
3),  preincubation of the cells with II,2 was absolutely re- 
quired for the detection of the ~/chain (compare-11,2 and 
+ I1,2 in Fig. 4). The ratio of 3/to/3 in the patient samples 
sharply contrasted with the approximately equal levels of/3 
and 3' chain precipitated from"  YT cell lysates (Fig. 3 B and 
Fig. 4). 
As noted, only a fraction of the/3 chains expressed on the 
patient NK cells bound 11,2 with an intermediate affinity 
(14), while for YT cells the level of/3 chain expression (41) 
roughly matched the number of intermediate-affinity binding 
sites (7, 8, 11-14). Thus, for both cell types the relative abun- 
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Associated with p70 IL-2R ~  Chain on Patient Post-IL-2-therapy 
NK Cells and YT Cells 
p64 (relative level*) 
Patient  - IL-2  + IL-2 
YT 
16  0.72  13.3 
19  0.65  11.0 
19'  0.33  10.8 
25  -  25.4 
27  0.64  6.3 
28  0.28  7.0 
29  0.13  9.3 
Exp. 
1  -  111 
1'  -  140 
2  0.9  121 
3  -  168 
4  0  112 
5s  2.8  60.4 
* The level of p64 IL-2R 3' chain is presented relative to the level of 
p70 B chain expression in the same gel. Presentation of the data as such 
depends on the assumption that the efEdency of iodination of ~ and 3~ 
chains is comparable in any given experiment. The level of ~ chain ex- 
pression was arbitrarily assigned a value of 100, such that a value of p64 
expression of 11 indicates the level of p64 was 11% that of p70. The 
observation that values of p64 relative to B varied ~100% in the experi- 
ments with YT may reflect subtle differences  in the degree of iodination 
of these two proteins or deviation from a 1:1 stoichiometry in a given 
experiment. 
* Immunoprecipitations were performed with  mAb  561. All  others 
shown were with mAb 341. 
S Indicates experiment in which the thiol-cleavable  crosslinker DSP was 
added to cells after incubation with or without IL-2. 
dance of 3' chain in the immunoprecipitates  approximated 
the proportion of 3 chains present in an intermediate-affinity 
state on the cell surface.  The low level of 3' chain detected 
on patient NK cells was not due to failure to quantitatively 
immunoprecipitate  the 3/3" complex,  since reprecipitation 
of lysates previously  treated  with  mAb  341  revealed that 
>95%  of the/~3' complexes were cleared by the first treat- 
ment with antibody (data not shown). Results similar to that 
shown in Fig. 4 were obtained in five separate experiments 
in which six individual patients' NK cells were analyzed after 
in vivo IIr  treatment.  These results (Table 2) demonstrate 
that in every case only a small fraction of the ~  chains ex- 
pressed on the surface of patient NK cells was physically as- 
sociated with the 3" chain.  This observation, together with 
the low levels of Ib2 binding that we have detected on these 
cells,  suggests that  the 3' chain is not only present  as part 
of the IL-2R complex on the patient  NK cells,  but that  it 
may be the component necessary for the ~ chain to assume 
a conformation that allows a stable interaction with Ib2 to 
oCCUr. 
In a previous study (19) it had been shown that isolated 
chains expressed on the surface of fibroblasts (CHO/~ cells) 
bound IL2 with a very low affinity. Furthermore, once bound, 
IL-2 dissociated rapidly from the isolated/~ chains (t,~ =  1.6 
min). This contrasted with/~ chains expressed as intermediate- 
affinity receptors, from which I1.-2 dissociated more slowly 
(t,/~  =  255  rain).  Similarly,  c~//~ complexes  expressed  in 
fibroblasts bound IL-2 with an equilibrium Ka approaching 
high  affinity,  but had relativdy rapid  rates of dissociation 
(t,~ =  18.5 min) (19).  Based on these observations and the 
proposed role of the 3` chain as a modulator  of the ability 
of the B chain to bind IL-2, it was of interest to determine 
whether any 3' chain could be detected in CHO cells expressing 
either the full-length/3  chain  (CHO/3)  or both ol and/~ 
chains (CHO od/~). CHO transfectants were iodinated and 
incubated with Ib2.  After detergent solubilization,  lysates 
were immunoprecipitated  with mAb 341  and analyzed by 
2-D IEF SDS-PAGE. As shown in Fig.  5, no 3' chain was 
detected in fibroblasts expressing either the B chain alone or 
the ~/B complex.  Identical results were obtained in three 
separate experiments,  in both the presence and absence of 
chemical crosslinking with DSP, arguing that the failure to 
detect 3' chain was not due to a more rapid dissociation of 
II:2 from the receptors. 
Discussion 
Soon after the o~ and/3 chains of the IL-2R were cloned, 
sequenced, and reexpressed in nonlymphoid cell backgrounds, 
it became clear that  a simple od3  structure  could not ac- 
count for the Ib2 binding and signal transducing character- 
istics of the Ib2R (15, 16, 19). The Ib2 binding sites created 
by expressing recombinant  ~/chain  in fibroblast cells were 
of a very low affinity (Ka  =  70 nM [19]),  in sharp contrast 
to the intermediate-affinity binding (Ka  =  0.5-2 nM) usu- 
ally associated with the B chain on lymphoid ceils. Our studies 
of NK cells recovered from patients  receiving Ib2 therapy 
proved that this was not simply the result of expressing the 
/3 chain in a nonlymphoid background, since the level of/~ 
chain expression on these NK cells greatly exceeded the level 
of intermediate-affinity IL-2 binding (14).  Furthermore,  al- 
though coexpression of ot and B chains on fibroblasts gave 
rise to binding  sites of relatively high affinity (15,  16,  19), 
such sites had a rapid dissociation rate when compared with 
high-affinity receptor sites on lymphoid cells (19) and were 
unable to transduce a signal (16). In addition to the discrepan- 
cies in binding affinity between recombinant/~ chain and/~ 
chain expressed on lymphoid cells,  it was evident from the 
B chain amino acid sequence that it contained no consensus 
tyrosine kinase domains (15). Yet, a number of studies had 
demonstrated that the activation of tyrosine kinase activity 
was a rapid event that followed stimulation of cells with IL-2 
(42-46). Thus, the evidence supports the notion that func- 
tional II:2R contain, in addition to o~ and/3 chains, one or 
more lymphoid specific components necessary for modulating 
537  Voss et al. Figure 4.  Analysis of IL-2R B and 3' chain expression 
on NK cells obtained after in vivo IL-2 therapy: low level 
of p64 3' chain expression correlates with low levels of 
II.-2 binding. YT cells and NK cells obtained from two 
representative patients who received in vivo continuous 
infusion Ib2 were surface iodinated with Iodogen as de- 
scribed in Materials and Methods. Pt. 19 posttherapy NK 
cells had been cryopreserved and were ,x,94-96% CD56 + 
CD3-. Pt. 28 NK cells were obtained by depletion  of 
CD5 + T  cells from  freshly obtained  posttherapy  PBL 
using a MACS cell sorter (25). Purity of T cell-depleted 
NK cells was >98%.  Iodinated cells were incubated in 
the presence (+) or absence (-) of 80 nM lb2 for 2 h 
on ice, followed by sohbilization in 0.5%  NP-40 lysis 
buffer. After  preclearing with nonspecific IgG agarose 
beads, lysates were immunoprecipitated  with either con- 
trol IgG agarose beads or mAb 341-coupled Sepharose 
beads. Immunoprecipitates  were analyzed  by 2-D IEF SDS- 
PAGE. First-dimension IEF gels are oriented acidic (H +) 
to basic (-OH) (left to right). Standard molecular masses 
are indicated at the left. Stained, fixed, and dried gels were 
exposed to phophorimaging screens for 4-5 d. 
the affinity of II:2 binding and transducing a signal from 
the receptor complex. 
In the study presented here, we have focused on identifying 
a structural component of the functional Ib2R expressed on 
human NK cells (14, 47) that could confer on the/3 chain 
the ability to bind IL-2 with intermediate affinity. Using two 
novel mAbs directed against the IL-2R 3  chain, our results 
indicate that intermediate-affinity Ib2 binding sites on YT 
cells,  and on NK cells obtained from patients after in vivo 
I1.-2 therapy, are composed of a/3 chain and an associated 
protein of 64 kD. This II:2R-associated protein had been pre- 
viously observed in high-affinity IL-2R complexes expressed 
on the surface of the leukemic cell line MT-2, and it was pro- 
posed that p64 be designated Ib2R 3' chain (24).  Based on 
the finding that ce, 3,  and 3, chains could coprecipitate as 
a receptor complex, it was possible that the 3' chain was as- 
sociated with either the ol or 3  chain, or both. Our studies 
of intermediate-affinity  receptor-bearing cells extend these ear- 
lier observations, showing that the 3' chain is physically as- 
sociated with the/3 chain and can be detected in freshly ob- 
tained peripheral blood cells. The association of~ and y  was 
only observed when II-2 was bound in the receptor com- 
plex.  No association of these two proteins was detected in 
the absence of IL-2, even when chemical crosslinkers were 
used to covalently couple cell surface molecules before lysis 
(Table  2). 
Examination of  patients' post-Ib2 therapy NK cells showed 
a low level of 3' chain expression relative to the high level 
of/3 chain expression. The amount of ~  chain that was as- 
sociated with the B chain correlated roughly with the low 
level of intermediate-affinity II~2 binding detected on these 
cells. We have never been able to detect more than '~1,500- 
2,000  intermediate-affinity Ib2  binding sites  on post-IL-2 
therapy NK cells, despite reproducibly observing levels of/~ 
chain expression that exceeded that observed on YT cells, 
which have 10-fold higher levels of intermediate-affinity Ib2 
binding (14, and our unpublished observations).  We were 
also unable to detect any 3' chain association with the ~ chain 
in cDNA-transfected fibroblast cells that expressed the/3 chain, 
a result in agreement with the fact that no intermediate-affinity 
IL-2 binding is detected on these cells. Similarly, no ~/3' as- 
sociation was detected on cDNA-transfected fibroblasts that 
expressed both ol and/3 chains. These cells bind Ib2  with 
a relatively high affinity but have a rapid rate of dissociation 
of Ib2 from the receptor complex (19). These findings sup- 
port the notion that the p64 y  chain may function to en- 
hance the affinity with which the B chain binds IL-2 mainly 
by slowing the rate with  which Ib2  dissociates  from the 
receptor. 
Saito et al.  (22),  using 12sI-Ib2 crosslinking to detergent 
sohbilized lymphoid cells, have described a molecule, p56, 
that formed a stable complex with the/3 chain in solution. 
It is possible that this molecule is the same as the 'y chain 
we have described here and that the difference in size esti- 
mates reflects differences in methodology. Indeed, in prelim- 
inary experiments we have evidence to suggest that it may 
be possible  to crosslink l~sI-Ib2  to  the 3' chain,  although 
this only demonstrates that the two molecules lie in close 
proximity (within 12 A) to one another on the cell surface, 
and not that the y  chain is an IL-2 binding protein. It is also 
possible that some other lymphoid cell-specific molecule as- 
sociates with the/3 chain, allowing the subsequent associa- 
tion of the 3' chain. However, under the iodination and im- 
munoprecipitation conditions used, and given the sensitivity 
of detection of the phosphorimager used in these studies, this 
seems unlikely. If other molecules are required, then our data 
would indicate they may not have available residues exposed 
on the cell surface that can be iodinated. 
These results point to the 3' chain as being involved in es- 
tablishing the structural integrity of the IL-2R.  Given the 
538  Association of the p64 ID2R 3' Chain with the IL-2R B Chain Figure 5.  Analysis  of  II..2R complexes  isolated  from  cDNA-transfected 
fibroblast cells: nonlymphoid  cells do not express  the p64 IL-2R  3, chain. 
CHO cells, expressing  either  the full-length  IIr  B chain  eDNA (CHO 
/3) (,4), or both full-length  ot and/3 chain  cDNAs (CHO ~x//3) (/3) were 
surface  iodinated  with Iodogen.  After  incubation  in I1.,2, cells  were  lysed 
in 0.5% NP-40  lysis  buffer.  After  preclearing,  lysates  were  immunoprecip- 
itated  with either  control  IgG1 agarose  beads  or mAb 341-coupled  Sepharose 
beads. Immunoprecipitates  were analyzed  by 2-D IEF SDS-PAGE. First- 
dimension  IEF gels are oriented  acidic  (H +) to basic (-OH) (left  to right). 
Standard molecular  masses (kD) are indicated  at the left. Stained, fixed, 
and dried  gels were  exposed  to phophorimaging  screens  for 4 d. The ex- 
periments shown are representative  of experiments  performed  on three 
separate occasions  with different  independently  transfected  CHO lines. 
finding that tyrosine phosphorylation of a number of sub- 
strates, including the/3 chain, is observed after stimulation 
with I1:2 (42-46, 48), it would be attractive to speculate that 
the 3' chain is also the Ib2K-associated tyrosine kinase. The 
absence of a consensus tyrosine kinase domain in the/3 chain 
(15, 49) suggests that the 13 chain, like many receptors not 
possessing intrinsic kinase activity, associates with and acti- 
vates a kinase, and then in turn serves as a substrate for the 
associated kinase. The phosphorylated tyrosine residues on 
the/3 chain are not essential for signaling, however, since mu- 
tation of these residues had no effect on Ib2-mediated sig- 
naling through the receptor (49). Hatakeyama et al. (38) have 
proposed that p56  lck may be associated with the/3 chain and 
function as an II~2R-assodated kinase. Fully functional IL-2R 
complexes containing kinase activity, however, have been pre- 
pared from cells negative for p56  lck expression (50). Further- 
more, mapping of the site of interaction of p56  lck with the 
/3 chain revealed that lck interacts with the B chain at residues 
shown to be dispensable for IL-2R signaling (38, 49), making 
it unclear what essential role p56  lck has in Ib2R signaling. 
Sugamura et al.  (51) have observed that the 64-kD IL-2R 3, 
chain protein is rapidly phosphorylated on tyrosine after stim- 
ulation  with  IL-2 and  have  speculated that  it  may be  an 
IL.2R-associated kinase.  Michiel et al.  (52),  however, have 
evidence suggesting that another molecule, pp97,  and not 
the 64-kD 3' chain, is the tyrosine kinase physically associated 
with the IL-2R. Their studies using renaturation kinase assays 
(50) have further demonstrated that tyrosine kinase activity 
could be reconstituted from pp97 electrophoretically sepa- 
rated from Ib2R-containing immune complexes, a result con- 
sistent with the identification of pp97 as an Ib2R-associated 
tyrosine kinase. 
From these studies it is evident that solving the structure 
of the Ib2R,  both in terms of its Ib2 binding properties 
and its signaling requirements, is far more challenging than 
initially anticipated. The evidence presented here has opened 
up a new pathway through which IL-2/II~2R interactions 
and cellular responses to IL-2 might be regulated. Such a model 
predicts that the level of p64 3' chain expression would regu- 
late the affinity of both the/3 chain and ot/B complexes by 
controlling the rate of dissociation of IL-2 from the receptor 
complex. Under this hypothesis, even the binding of II:2 to 
c~/13 complexes (which occurs with relatively high affinity) 
would not lead to a functional cellular response due to the 
lack of sustained binding to the receptor. A similar role for 
an "affinity modulating" element associated with a ligand 
binding subunit has been described for the IL-6R (53), where 
GP130 serves to regulate both the level of high-affinity IL-6 
binding  and  possibly  signal  transduction.  It  is  not  clear 
whether, even in the presence of the 3' chain we describe, 
one could reconstitute fully functional IL-2R.  There may be 
a further requirement for additional receptor-associated sig- 
naling molecules, such as pp97 (50,  52).  The pursuit of fu- 
ture studies will greatly benefit from the cloning of the 3' 
chain. Given the close homology between the Ib2K B chain 
and other members of the hematopoietin receptor superfamily 
(54), solving the structure of this receptor complex may also 
yield insight into the structural and functional requirements 
of other cytokine receptors. 
Final Note.  While this manuscript was in review,  a re- 
port by Takeshita et al. (55) appeared that demonstrated, similar 
to the findings we have presented here, that the level of II:2R 
3' chain associated with/3 chain in intermediate-affinity  Ib2R 
correlated directly with the level of II.-2 binding. This same 
report also demonstrated, as have we, the absence of 3' chain 
in fibroblasts transfected with the/3 chain. Thus, the results 
of these two independent studies are consistent with the IL-2R 
3'  chain  playing  an  important  role in  determining IL-2R 
affinity. 
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